Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate ...

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%.

A UCLA study shows that a new treatment combining a radioactive drug with radiation therapy could help delay hormone therapy ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer ...

SBRT may ease toxicity, but the lower doses could come at the expense of cancer control, new data indicate. Experts suggest a ...

A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a ...

SpaceOAR Hydrogel is a polyethylene glycol–based hydrogel designed to create space between the prostate and rectum to reduce ...